Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD
November 26, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
Minutes are Consistent with Guidance Received at FDA Meeting More Than 50 Percent of Enrollment Completed for Phase 3 RECOVERY Trial of Tonmya for PTSD Results from RECOVERY Interim Analysis...
Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference
November 25, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer...
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
November 21, 2019 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that, having...
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder
November 20, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has received the...
Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering
November 20, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), clinical-stage biopharmaceutical company, announced today the closing of its...
Tonix Pharmaceuticals Prices $9.0 Million Public Offering
November 15, 2019 08:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an...
Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
November 08, 2019 16:45 ET
|
Tonix Pharmaceuticals Holding Corp.
50% of Enrollment Complete for Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD Results from RECOVERY Interim Analysis Expected First Quarter 2020 Topline Data Expected Second...
Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting
November 04, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Primary Endpoint Will be Mean Change from Baseline in CAPS-5 at Week 12, Instead of Week 4 Results from Added Interim Analysis Expected in First Quarter 2020 Topline Data Expected in Second Quarter...
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
October 31, 2019 13:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect...
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601
October 23, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S....